Replimune kickstarts Phase III melanoma trial studying RP1 immunotherapy

IGNYTE-3 is a Phase III trial investigating Replimune’s flagship oncolytic treatment for advanced, treatment-resistant melanoma.

Aug 15, 2024 - 04:00

Replimune kickstarts Phase III melanoma trial studying RP1 immunotherapy

IGNYTE-3 is a Phase III trial investigating Replimune’s flagship oncolytic treatment for advanced, treatment-resistant melanoma.

Read the original article

Tags:

Previous Article

CNIO researchers discover a ‘switch’ for the desire to engage in physical activi...

Kezar stalls solid tumour trial to focus on autoimmune disease candidate

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Merck buys Mirus Bio to boost viral vector bioprocessing capacity

Merck buys Mirus Bio to boost viral vector bioprocessin...

Aug 3, 2024

Pieris Pharma lays off 70% of workforce amid company restructuring

Pieris Pharma lays off 70% of workforce amid company re...

Jul 19, 2023

STAT+: Biden administration makes opening offers in Medicare drug price negotiations

STAT+: Biden administration makes opening offers in Med...

Feb 1, 2024